期刊文献+

盐酸伊立替康脂质体的制备及体外抗肿瘤活性 被引量:5

Preparation and in vitro Antitumor Activity of Irinotecan Hydrochloride Liposomes
原文传递
导出
摘要 采用硫酸铵梯度法制得了平均粒径为(45.3±12.6)nm、包封率为(93.8±0.7)%的盐酸伊立替康脂质体。制品在pH7.4磷酸盐缓冲液中约120 h释放完全,提示其具有缓释作用。体外细胞毒性试验显示,制品在较高浓度(25 g/ml以上)对人结肠癌细胞株HT-29的抑制作用稍优于游离药物,IC50分别为28.1和33.0 g/ml。细胞凋亡试验表明,30 g/ml的脂质体和游离药物均能诱导HT-29细胞的凋亡,与游离药物相比,脂质体具有更强的凋亡诱导效果。 The irinotecan hydrochloride liposomes with the mean particle size and entrapment efficiency of (45.3±12.6) nm and (93.8±0.7) % were prepared by ammonium sulfate gradient method. The drug was released completely from the liposomes within 120 h in phosphate buffer (pH 7.4) in a manner of sustained release. Compared with the free drug, the prepared liposomes showed slightly higher in vitro cytotoxicity on human colorectal cancer HT-29 cells at relatively high concentration (above 25μg/ml). The ICs0 values of the product and free drug were 28.1 and 33.0 ~tg/ml, respectively. Both liposomes and free drug could induce apoptosis of HT-29 cells at the drug concentration of 30μg/ml, but the liposomes exhibited a stronger effect on the induction of cell apoptosis than free drug.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2013年第6期576-580,共5页 Chinese Journal of Pharmaceuticals
关键词 盐酸伊立替康 脂质体 制备 硫酸铵梯度法 体外抗肿瘤活性 irinotecan hydrochloride liposome preparation ammonium sulfate gradient method in vitro antitumor activity
  • 相关文献

参考文献9

二级参考文献72

  • 1张新玉,田辉.遗传性非结合型高胆红素血症[J].肝脏,2005,10(1):51-52. 被引量:5
  • 2雷国峰,陈琳,邓英杰,钟海军,郝爱军,张丽娜.超滤法-HPLC法测定灯盏花素脂质体包封率[J].沈阳药科大学学报,2006,23(4):237-239. 被引量:23
  • 3孙维彤,黄桂华,叶杰胜,张娜.鱼精蛋白凝聚法测定脂质体和纳米脂质体包封率[J].中国药学杂志,2006,41(22):1716-1720. 被引量:35
  • 4秦晶,陈大为,乔明曦,胡海洋,赵秀丽,陈宝玉.微柱离心法测定阿魏酸脂质体的包封率[J].中国药学杂志,2007,42(14):1116-1117. 被引量:22
  • 5Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I -DNA cleavable complexes: studies in a cell-free SV dO DNA replication system [J]. Cancer Res.,1993,53(24): 5908-5914.
  • 6Rougier P, Van Custem E, Bajetts E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [J]. Lancet,1998,352 (9138):1407.
  • 7Euan Ramsay, Jehan Mnajim, Malathi Anantha, et al. A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention [J]. European Journal of Pharmaceutics and Biopharmaceuties,2008,(68):607-617.
  • 8Awa Dicko, Paul Tardi, Xiaowei Xie, et al. Role of copper gluconate/ triethanolamine in irinotecan encapsulation inside the liposomes [J]. International Journal of Pharmaceutics,2007,(337):219-228.
  • 9Zhang JA, Xuan T, Parmar M, et al. Development and characterization of a novel liposome-based formulation of SN-38[J].International Journal of Pharmaceuties,2004 270(122):93-107.
  • 10Mura P, Maest relli F, Gonzalez2Rodriguez M, et al. Development, characterization and in vivo evaluation of benzocaine-loaded liposomes[J]. European Journal of Phannaceutics and Biopharmaceutic,2007,67 (1): 86-95.

共引文献27

同被引文献57

  • 1魏伟,邓英杰,张睿智,曹金娜,李文秀,高晓非.硫酸铵梯度法制备盐酸伊立替康脂质体及体外释放的研究[J].中国药剂学杂志(网络版),2009(1):20-30. 被引量:7
  • 2胡连栋,唐星,崔福德.全反式维甲酸固体脂质纳米粒的制备及体内外评价[J].药学学报,2005,40(1):71-75. 被引量:20
  • 3代广会,周卿,尚京川.固相萃取-高效液相色谱法测定细胞内外米托蒽醌的含量[J].药物分析杂志,2007,27(7):1075-1077. 被引量:7
  • 4Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy[J]. Cancer Res, 2006, 66(6) :3 271.
  • 5Garbuzenko O; Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer[J]. Chem Phys Lipids, 2005,135 (2) : 117.
  • 6Xu H, Deng Y, Chen D, et al. Esterase-catalyzed dePE- Gylation of pH-sensitive vesicles modidied with cleavable PEG-lipid derivatives[J]. J Control Release, 2008, 130 (3):238.
  • 7Arpicco S, Lerda C, Dalla Pozza E, et al. Hyaluronic acid-coated liposomes for active targeting of gemcitabine [J]. EurJ Pharm Biopharm, 2013, 85 (3 Pt A): 373—380.
  • 8Zhou J, Zhao R, Wen F, et al. Cost-effectiveness analysis ofgemcitabine, S-l and gemcitabine plus S-l for treatment ofadvanced pancreatic cancer based on GEST study [J]. MedOncol 2015,32 (4): 121.
  • 9Kim JS, Park TH, Lee KS, et al. Outcomes of palliativeweekly low-dose gemcitabine-Cisplatin chemotherapy inanthracycline- and taxane- pretreated metastatic breast cancerpatients [J]. J Breast Cancer, 2014,17 (4): 339—343.
  • 10Bouffard DY, Laliberte J, Momparler RL. Kinetic studieson 2',2,-difluorodeoxycytidine (Gemcitabine) with purifiedhuman deoxycytidine kinase and cytidine deaminase [J].Biochem Pharmacol, 1993, 45 (9); 1857—1861.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部